Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.80 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980849 | 0.91 | METAP2 (0.75) | METAP2GLO1MMP2 | |
| SCHEMBL3981921 | 0.90 | METAP2 (0.85) | METAP2GLO1MMP2SLC40A1 | |
| SCHEMBL3983775 | 0.89 | METAP2 (1.00) | METAP2GLO1MMP2SLC40A1 | |
| SCHEMBL3984405 | 0.81 | METAP2 (0.73) | METAP2GLO1MMP2SLC40A1 | |
| SCHEMBL4272722 | 0.78 | METAP2 (0.69) | METAP2GLO1MMP2SLC40A1 | |
| SCHEMBL3984369 | 0.78 | METAP2 (0.69) | METAP2GLO1MMP2SLC40A1 | |
| SCHEMBL3984043 | 0.77 | METAP2 (0.64) | METAP2GLO1MMP2 | |
| SCHEMBL3982725 | 0.77 | METAP2 (0.74) | METAP2GLO1MMP2 | |
| SCHEMBL4251305 | 0.75 | METAP2 (0.67) | METAP2GLO1MMP2SLC40A1 | |
| SCHEMBL3981979 | 0.73 | METAP2 (0.67) | METAP2GLO1MMP2SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885GLO1 639/4885MMP2 90/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885GLO1 639/4885MMP2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.